Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2007; 50:2061-2067, doi:10.1016/j.jacc.2007.08.021 (Published online 5 November 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Online Appendix
Right arrow All Versions of this Article:
j.jacc.2007.08.021v1
50/21/2061    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kilcullen, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kilcullen, N.
Related Collections
Right arrowRelated Articles

CLINICAL RESEARCH: BIOMARKER

Heart-Type Fatty Acid-Binding Protein Predicts Long-Term Mortality After Acute Coronary Syndrome and Identifies High-Risk Patients Across the Range of Troponin Values

Niamh Kilcullen, MRCPI*,2,*, Karthik Viswanathan, MRCP*,3, Rajiv Das, MRCP*,2, Christine Morrell*, Amanda Farrin, MSc{dagger}, Julian H. Barth, MD, FRCP, FRCPath{ddagger},1, Alistair S. Hall, PhD, FRCP*,1 for the EMMACE-2 Investigators

* Coronary Artery Disease Clinical Research Network Group, Leeds Institute for Genetic, Health & Therapeutics, Leeds, United Kingdom
{dagger} Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom
{ddagger} Department of Clinical Biochemistry, General Infirmary at Leeds, Leeds, United Kingdom.

Manuscript received November 6, 2006; revised manuscript received July 23, 2007, accepted August 21, 2007.

* Reprint requests and correspondence: Dr. Niamh Kilcullen, C-NET Group, Clinical Cardiology, G Floor Jubilee Building, General Infirmary at Leeds, Leeds, LS1 3EX Yorkshire, United Kingdom. (Email: niamhkilcullen{at}doctors.org.uk).

Objectives: Our aim was to determine if a high-performance assay for heart-type fatty acid-binding protein (H-FABP) has a role in predicting all-cause mortality after acute coronary syndrome (ACS).

Background: Heart-type fatty acid-binding protein is released into the circulation following myocardial ischemia and necrosis and therefore may be of value to physicians when caring for patients admitted to hospital with a clinical diagnosis of ACS.

Methods: This was a prospective observational study with a follow-up of 12 months. The H-FABP was measured 12 to 24 h after onset of symptoms in 1,448 patients admitted to hospital with ACS. The main outcome measure was all-cause mortality 1 year after index hospital admission. Multivariable analyses were conducted using the well validated GRACE (Global Registry of Acute Coronary Events) variables together with troponin I and highly sensitive C-reactive protein (hs-CRP).

Results: After 12 months of follow-up, 296 patients had died. Multivariable analysis demonstrated that H-FABP quartiles were strongly predictive of outcome: Q1 hazard ratio (HR) 1.0; Q2 HR 2.32 (95% confidence interval [CI] 1.25 to 4.30; p = 0.007); Q3 HR 3.17 (95% CI 1.73 to 5.82; p < 0.001); Q4 HR 4.88 (95% CI 2.67 to 8.93; p < 0.001). The crude all-cause 1-year mortality for unstable angina patients with H-FABP <5.8 µg/l was 2.1% compared with 22.9% for patients above this cutoff. The adjusted all-cause mortality HR in this group was 11.35 (95% CI 2.00 to 64.34; p = 0.006).

Conclusions: Heart-type fatty acid-binding protein predicts long-term mortality after ACS and identifies high-risk patients in a manner that is additive to the GRACE clinical risk factors, troponin, and hs-CRP, possibly as a result of identifying the occurrence of myocardial ischemia with or without necrosis.

Abbreviations and Acronyms
  ACS = acute coronary syndrome
  CV = coefficient of variation
  ECG = electrocardiogram
  H-FABP = heart-type fatty acid-binding protein
  hs-CRP = highly sensitive C-reactive protein
  MI = myocardial infarction
  TnI = troponin I


Related Articles

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2007 50: A31-A32. [Full Text] [PDF]

The Skinny on Fatty Acid-Binding Protein
James A. de Lemos and Michelle O’Donoghue
J. Am. Coll. Cardiol. 2007 50: 2068-2070. [Full Text] [PDF]



This article has been cited by other articles:


Home page
HeartHome page
J. A. Shand, D. J. McEneaney, and I. B. Menown
Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction: a systematic review and meta-analysis
Heart, April 1, 2011; 97(7): 605 - 605.
[Full Text] [PDF]


Home page
Anesth. Analg.Home page
J. D. Muehlschlegel, T. E. Perry, K.-Y. Liu, A. A. Fox, C. D. Collard, S. K. Shernan, and S. C. Body
Heart-Type Fatty Acid Binding Protein Is an Independent Predictor of Death and Ventricular Dysfunction After Coronary Artery Bypass Graft Surgery
Anesth. Analg., November 1, 2010; 111(5): 1101 - 1109.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. Viswanathan, N. Kilcullen, C. Morrell, S. J. Thistlethwaite, M. U. Sivananthan, T. B. Hassan, J. H. Barth, and A. S. Hall
Heart-Type Fatty Acid-Binding Protein Predicts Long-Term Mortality and Re-Infarction in Consecutive Patients With Suspected Acute Coronary Syndrome Who Are Troponin-Negative
J. Am. Coll. Cardiol., June 8, 2010; 55(23): 2590 - 2598.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Z. Goldhaber
Fine-Tuning Risk Stratification for Acute Pulmonary Embolism With Cardiac Biomarkers
J. Am. Coll. Cardiol., May 11, 2010; 55(19): 2158 - 2159.
[Full Text] [PDF]


Home page
HeartHome page
L.-p. He, X.-y. Tang, W.-h. Ling, W.-q. Chen, and Y.-m. Chen
Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies
Heart, March 1, 2010; 96(5): 339 - 346.
[Abstract] [Full Text] [PDF]


Home page
Ann Clin BiochemHome page
D P Bathia, D R Carless, K Viswanathan, A S Hall, and J H Barth
Serum 99th centile values for two heart-type fatty acid binding protein assays
Ann Clin Biochem, November 1, 2009; 46(6): 464 - 467.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
S. E. Orfanos and S. Zakynthinos
Heart biomarkers as prognostic tools for chronic thromboembolic pulmonary hypertension: a step forward by the fatty acid-binding protein
Eur. Respir. J., May 1, 2008; 31(5): 915 - 917.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the Year in JACC 2007
J. Am. Coll. Cardiol., January 29, 2008; 51(4): 490 - 512.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. A. de Lemos and M. O'Donoghue
The Skinny on Fatty Acid-Binding Protein
J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2068 - 2070.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement